statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday...

Spotlight on Alnylam Pharmaceuticals: Analyzing the Surge in Options Activity

Peering Into Alnylam Pharmaceuticals's Recent Short Interest

Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today

On Monday, major U.S. indices showed mixed performance. The Dow Jones Industrial Average closed up by nearly 0.7% at 39,411.21,
read more...

Successful heart drug trial prompts Alnylam stock to jump 35 percent

The successful results of a heart drug's late-stage clinical trial have prompted Alnylam Pharmaceuticals' stock to jump 35 percent, according to the Wall Street Journal. Read more...

Alnylam Stock Soars on Strong Results in Heart Drug Study

Getty Images

 Key TakeawaysAlnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular...

Futures Flat As Nvidia Slides For Third Day

Futures Flat As Nvidia Slides For Third Day

 Futures are flat, set for a muted open after erasing an earlier drop, and trading at record highs after three straight weeks of gains ahead of...

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi...

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Volume	524,476.00
52-Wk High	$263.73
52-Wk Low	$141.98

ALNY Alnylam Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals